InsiderTrades.com logo
Edward Carr net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Edward Carr Biography and Net Worth

Chief Accounting Officer of Dianthus Therapeutics

Mr. Carr is a veteran financial leader with over 30 years of finance and public accounting experience including managing financial operations, financial reporting (including SEC reporting), technical accounting, internal controls, financial planning, treasury, and taxation. Prior to Dianthus, Mr. Carr served as Chief Financial Officer of Abeona Therapeutics, a publicly traded, clinical stage biotechnology company. Prior to Abeona, Mr. Carr served as Assistant Controller at Coty Inc., a multi-billion dollar, publicly traded manufacturing company and as Chief Accounting Officer at Foster Wheeler AG, a multi-billion dollar, publicly traded engineering and construction company. Mr. Carr, who is a Certified Public Accountant, began his career at Ernst & Young LLP. He received his Master of Professional Accountancy and Bachelor of Business Administration from West Virginia University.

What is Edward Carr's net worth?

The estimated net worth of Edward Carr is at least $1.59 million as of September 17th, 2026. Mr. Carr owns 20,000 shares of Dianthus Therapeutics stock worth more than $1,590,400 as of October 28th. This net worth approximation does not reflect any other investments that Mr. Carr may own. Learn More about Edward Carr's net worth.

How do I contact Edward Carr?

The corporate mailing address for Mr. Carr and other Dianthus Therapeutics executives is 7 Times Square, 43rd Floor, New York, NY, 10036. Dianthus Therapeutics can also be reached via phone at (929) 999-4055 and via email at [email protected]. Learn More on Edward Carr's contact information.

Has Edward Carr been buying or selling shares of Dianthus Therapeutics?

Edward Carr has not been actively trading shares of Dianthus Therapeutics during the last quarter. Most recently, Edward Carr sold 20,000 shares of the business's stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $101.38, for a transaction totalling $2,027,600.00. Following the completion of the sale, the chief accounting officer now directly owns 20,000 shares of the company's stock, valued at $2,027,600. Learn More on Edward Carr's trading history.

Who are Dianthus Therapeutics' active insiders?

Dianthus Therapeutics' insider roster includes Edward Carr (Chief Accounting Officer), Marino Garcia (President & Chief Executive Officer, Board Member), Anne McGeorge (Director), Simrat Randhawa (Insider), Simon Read (Director), Ryan Savitz (CFO), and Adam Veness (SVP). Learn More on Dianthus Therapeutics' active insiders.

Are insiders buying or selling shares of Dianthus Therapeutics?

During the last twelve months, insiders at the sold shares 19 times. They sold a total of 869,767 shares worth more than $68,951,330.79. The most recent insider tranaction occured on September, 17th when CAO Edward Carr sold 20,000 shares worth more than $2,027,600.00. Insiders at Dianthus Therapeutics own 3.0% of the company. Learn More about insider trades at Dianthus Therapeutics.

Information on this page was last updated on 9/17/2026.

Edward Carr Insider Trading History at Dianthus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/17/2026Sell20,000$101.38$2,027,600.0020,000View SEC Filing Icon  
3/12/2026Sell43,682$81.49$3,559,646.18View SEC Filing Icon  
See Full Table

Edward Carr Buying and Selling Activity at Dianthus Therapeutics

This chart shows Edward Carr's buying and selling at Dianthus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Dianthus Therapeutics Company Overview

Dianthus Therapeutics logo
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Read More

Today's Range

Now: $79.52
Low: $78.64
High: $81.10

50 Day Range

MA: $94.59
Low: $72.09
High: $115.54

2 Week Range

Now: $79.52
Low: $32.28
High: $117.88

Volume

748,687 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A